Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 2Terminated 1

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5

Conditions

Burkitt Lymphoma 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Meningeal Carcinomatosis 7Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 6Lymphoma, Large B-Cell, Diffuse 5Leukemia, Myeloid, Acute 5Leukemia, Biphenotypic, Acute 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Glioblastoma 3Astrocytoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplastic Cells, Circulating 2Meningeal Neoplasms 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell 2Lymphoma 2Glioma 2Brain Neoplasms 2Vomiting 1Uveal Melanoma 1Rhabdomyosarcoma 1Psychomotor Agitation 1Pain, Postoperative 1Oligodendroglioma 1Nevus 1Neoplasm Recurrence, Local 1Multiple Myeloma 1

Interventions

Rituximab 416Cyclophosphamide 348Vincristine 173Prednisone 172Doxorubicin 168Etoposide 160Peripheral Blood Stem Cell Transplantation 114Filgrastim 108Lenalidomide 97fludarabine phosphate 96Radiotherapy 80Cytarabine 80Gemcitabine 73Melphalan 66Mycophenolic Acid 64Cyclosporine 60Methotrexate 59Busulfan 57Ifosfamide 55Carmustine 55fludarabine 50Tacrolimus 50Whole-Body Irradiation 49Carboplatin 49polatuzumab vedotin 44Oxaliplatin 44Dexamethasone 44Antilymphocyte Serum 42ibrutinib 40Bendamustine Hydrochloride 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × Spinal Puncture × Clear all
NCT03984448 2026-05-13

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
363 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06784726 2026-05-06

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

University of Washington

Phase 2 Recruiting
27 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05359211 2026-03-20

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Fred Hutchinson Cancer Center

Phase 1 Active not recruiting
27 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07098364 2026-01-14

ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
33 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04933617 2024-07-09

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
8 enrolled 17 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡